COMPANY

Dignify Therapeutics

HQ: Research Triangle Park, NC source · dignifytherapeutics.com ↗ · Southeast

Dignify Therapeutics (Research Triangle Park, NC) is a clinical-stage company developing short-acting drugs for bowel and/or bladder emptying on demand. Its lead clinical-stage program DTI-117, a neurokinin-2 receptor agonist, has an FDA-cleared IND, and Dignify is initiating an NIH-funded Phase 1 study in healthy volunteers meant to lay groundwork for later evaluation in neurogenic bowel dysfunction. DTI-301, a TRPV1 agonist rectal suppository, is advancing toward Phase 1 in Australia. From company website Source · Oct 12, 2026

Keywords: therapeutics clinical-stage neurogenic bowel dysfunction urology NK2 receptor agonist Research Triangle Park, NC

Location: Research Triangle Park, NC · source · Oct 15, 2026

Profile checked Oct 10, 2026

31NIH grants

Funding and NIH signals

SEC Form D raise Raised $800K in debt securities (Form D filed Sep 25, 2026). SEC Form D 0001622906-26-000003 (Sep 25, 2026)
Evidence (1 event)
- Sep 25, 2026 · SEC Form D 0001622906-26-000003
  Name of Issuer: Dignify Therapeutics, LLC; CIK: 1622906; Address: Research Triangle Park, NC; Submission type: D; Filing date: 2026-09-25; Industry Group: Pharmaceuticals; Date of First Sale: 2026-09-15; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 800000; Federal exemptions: 06b
NIH award NIH awarded $95K (SBIR Phase II 3U44NS129628-04S1, supplement, notice Sep 3, 2026); 2 NIH awards totaling $294K in the last 12 months. NIH RePORTER 3U44NS129628-04S1 (Sep 3, 2026)
Evidence (2 events)
- Sep 3, 2026 · NIH RePORTER 3U44NS129628-04S1
  Organization: DIGNIFY THERAPEUTICS, LLC; City/State: RESEARCH TRIANGLE PARK, NC; Project number: 3U44NS129628-04S1; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 94793; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Preclinical and Early Clinical Development of a Novel Drug for On-Demand Voiding; Organization type: Domestic For-Profits
- May 5, 2026 · NIH RePORTER 5U44NS129628-04
  Organization: DIGNIFY THERAPEUTICS, LLC; City/State: RESEARCH TRIANGLE PARK, NC; Project number: 5U44NS129628-04; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-05-05; FY total cost (award amount): 199520; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Preclinical and Early Clinical Development of a Novel Drug for On-Demand Voiding; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Sep 3, 2026 Grant Government grant — SBIR: $94,793 (annual award, as published), announced Sep 3, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
May 5, 2026 Grant Government grant — SBIR: $199,520 (annual award, as published), announced May 5, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
Aug 11, 2025 Grant Government grant — SBIR: $110,040 (annual award, as published), announced Aug 11, 2025. Agency: NIH/NIA. Source: government award database. source ↗
Mar 7, 2025 Grant Government grant — SBIR: $976,908 (annual award, as published), announced Mar 7, 2025. Agency: NIH/NINDS. Source: government award database. source ↗

Funding

Last 2 years.

Sep 3, 2026 Government grant — SBIR: $94,793 (annual award, as published), announced Sep 3, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
May 5, 2026 Government grant — SBIR: $199,520 (annual award, as published), announced May 5, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
Aug 11, 2025 Government grant — SBIR: $110,040 (annual award, as published), announced Aug 11, 2025. Agency: NIH/NIA. Source: government award database. source ↗
Mar 7, 2025 Government grant — SBIR: $976,908 (annual award, as published), announced Mar 7, 2025. Agency: NIH/NINDS. Source: government award database. source ↗

NIH awards 31

Annual award amounts. Total $18.2M.

Sep 9, 2024 NIH award 1R43DK138600-01A1 FY2024: $391,458 awarded for that fiscal year; activity R43 (SBIR); PI THOR, KARL B; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Therapy for Fecal Incontin source ↗
Sep 4, 2024 NIH award 1R43AG088838-01 FY2024: $389,852 awarded for that fiscal year; activity R43 (SBIR); PI ZHANG, QIAOJUAN; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Novel treatment for urina source ↗
Apr 12, 2024 NIH award 4U44NS129628-02 FY2024: $1,473,895 awarded for that fiscal year; activity U44 (SBIR); PI BURGARD, EDWARD; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Preclinical and Early C source ↗
Jul 14, 2023 NIH award 3U44NS129628-01S1 FY2023: $42,503 awarded for that fiscal year; activity U44 (SBIR); PI BURGARD, EDWARD; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Preclinical and Early Cl source ↗
Feb 14, 2023 NIH award 1U44NS129628-01 FY2023: $499,393 awarded for that fiscal year; activity U44 (SBIR); PI BURGARD, EDWARD; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Preclinical and Early Cli source ↗
Jun 2, 2022 NIH award 3R44NS115169-03S1 FY2022: $50,000 awarded for that fiscal year; activity R44 (SBIR); PI THOR, KARL B; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Pudendal neuromodulation fo source ↗
Aug 31, 2021 NIH award 5R44NS115169-03 FY2021: $431,363 awarded for that fiscal year; activity R44 (SBIR); PI THOR, KARL B; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Pudendal neuromodulation for source ↗
Mar 30, 2021 NIH award 5U44NS106685-03 FY2021: $1,187,722 awarded for that fiscal year; activity U44 (SBIR); PI BURGARD, EDWARD; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Preclinical characteriz source ↗
Sep 22, 2020 NIH award 2R44NS115169-02 FY2020: $941,206 awarded for that fiscal year; activity R44 (SBIR); PI THOR, KARL B; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Pudendal neuromodulation for source ↗
Sep 21, 2020 NIH award 1R43DK125131-01A1 FY2020: $295,650 awarded for that fiscal year; activity R43 (SBIR); PI MARSON, LESLEY; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Neurokinin-2 receptor-in source ↗
Aug 24, 2020 NIH award 1R41NS117205-01 FY2020: $394,754 awarded for that fiscal year; activity R41 (STTR); PI RUPNIAK, NADIA MELANIE JOSEPHINE; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Examinat source ↗
Feb 25, 2020 NIH award 4U44NS106685-02 FY2020: $1,823,630 awarded for that fiscal year; activity U44 (SBIR); PI BURGARD, EDWARD; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Preclinical characteriz source ↗
Sep 25, 2019 NIH award 1R43NS115215-01 FY2019: $299,648 awarded for that fiscal year; activity R43 (SBIR); PI MARSON, LESLEY; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Intrarectal mechanorecepto source ↗
Sep 24, 2019 NIH award 1R41NS115169-01 FY2019: $269,371 awarded for that fiscal year; activity R41 (STTR); PI THOR, KARL B; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Pudendal neuromodulation for source ↗
Apr 2, 2019 NIH award 5R44DK112437-03 FY2019: $998,525 awarded for that fiscal year; activity R44 (SBIR); PI THOR, KARL B; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Development of a first-in-cl source ↗
Feb 1, 2019 NIH award 1U44NS106685-01A1 FY2019: $901,425 awarded for that fiscal year; activity U44 (SBIR); PI BURGARD, EDWARD; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Preclinical characteriz source ↗
Jul 11, 2018 NIH award 5R44AG055169-03 FY2018: $614,817 awarded for that fiscal year; activity R44 (SBIR); PI THOR, KARL B; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. An optimized NK2R agonist fo source ↗
Jun 20, 2018 NIH award 4R44DK112437-02 FY2018: $1,001,467 awarded for that fiscal year; activity R44 (SBIR); PI THOR, KARL B; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Development of a first-in- source ↗
Sep 8, 2017 NIH award 2R44AG055169-02 FY2017: $1,158,181 awarded for that fiscal year; activity R44 (SBIR); PI THOR, KARL B; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. An optimized NK2R agonist source ↗
Aug 22, 2017 NIH award 1R43AG057243-01 FY2017: $299,989 awarded for that fiscal year; activity R43 (SBIR); PI THOR, KARL B; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. A neurokinin receptor agonis source ↗
Aug 7, 2017 NIH award 1R44DK112437-01A1 FY2017: $300,000 awarded for that fiscal year; activity R44 (SBIR); PI THOR, KARL B; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Development of a first-in- source ↗
Aug 4, 2017 NIH award 5R42NS092178-03 FY2017: $411,356 awarded for that fiscal year; activity R42 (STTR); PI MARSON, LESLEY; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Delivery of peptides for i source ↗
Jul 12, 2017 NIH award 5R44HD080263-03 FY2017: $681,653 awarded for that fiscal year; activity R44 (SBIR); PI MARSON, LESLEY; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Development of a treatment source ↗
Sep 21, 2016 NIH award 2R42NS092178-02 FY2016: $953,265 awarded for that fiscal year; activity R42 (STTR); PI MARSON, LESLEY; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Delivery of peptides for i source ↗
Sep 16, 2016 NIH award 1R43AG055169-01 FY2016: $275,744 awarded for that fiscal year; activity R43 (SBIR); PI THOR, KARL B; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Identification of an optimiz source ↗
Aug 17, 2016 NIH award 5R21NS089880-02 FY2016: $351,000 awarded for that fiscal year; activity R21 (OTHER_NIH); PI MARSON, LESLEY; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Examination of a nove source ↗
Jul 6, 2016 NIH award 2R44HD080263-02A1 FY2016: $818,347 awarded for that fiscal year; activity R44 (SBIR); PI MARSON, LESLEY; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Development of a treatme source ↗
Sep 19, 2015 NIH award 1R21NS089880-01A1 FY2015: $350,000 awarded for that fiscal year; activity R21 (OTHER_NIH); PI MARSON, LESLEY; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Examination of a no source ↗
Apr 22, 2015 NIH award 1R43DK103392-01A1 FY2015: $199,192 awarded for that fiscal year; activity R43 (SBIR); PI MARSON, LESLEY; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Development of potential source ↗
Apr 6, 2015 NIH award 1R41NS092178-01 FY2015: $224,946 awarded for that fiscal year; activity R41 (STTR); PI MARSON, LESLEY; recipient as written: DIGNIFY THERAPEUTICS, LLC, RESEARCH TRIANGLE PARK, NC. Delivery of peptides for i source ↗